{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:33Z","timestamp":1792783413294,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"VLM"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01516-1","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T14:12:13Z","timestamp":1747923133000},"page":"959-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosis"],"prefix":"10.1007","volume":"64","author":[{"given":"Paulette","family":"Magnas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00efm","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Froelicher Bournaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Fesenbeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2023.104169","volume":"52","author":"I Fajac","year":"2023","unstructured":"Fajac I, Burgel P-R. Cystic fibrosis. Presse Med. 2023;52: 104169. https:\/\/doi.org\/10.1016\/j.lpm.2023.104169.","journal-title":"Presse Med"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"MA Mall","year":"2024","unstructured":"Mall MA, Burgel P-R, Castellani C, Davies JC, Salathe M, Taylor-Cousar JL. Cystic fibrosis. Nat Rev Dis Primers. 2024;10:53. https:\/\/doi.org\/10.1038\/s41572-024-00538-6.","journal-title":"Nat Rev Dis Primers"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195\u2013211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3.","journal-title":"Lancet"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;10:1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662.","journal-title":"Front Pharmacol"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8:65\u2013124. https:\/\/doi.org\/10.1016\/S2213-2600(19)30337-6.","journal-title":"Lancet Respir Med"},{"key":"1516_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107455","volume":"220","author":"A Gramegna","year":"2023","unstructured":"Gramegna A, Aliberti S, Calderazzo MA, Casciaro R, Ceruti C, Cimino G, et al. The impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: an expert-based Delphi consensus. Respi Med. 2023;220: 107455. https:\/\/doi.org\/10.1016\/j.rmed.2023.107455.","journal-title":"Respi Med."},{"key":"1516_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","volume":"208","author":"P McNally","year":"2023","unstructured":"McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, et al. Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older\u2014the RECOVER trial. Am J Respir Crit Care Med. 2023;208:917\u201329. https:\/\/doi.org\/10.1164\/rccm.202308-1317OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR8","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8.","journal-title":"Lancet"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Van Goor","year":"2014","unstructured":"Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13:29\u201336. https:\/\/doi.org\/10.1016\/j.jcf.2013.06.008.","journal-title":"J Cyst Fibros"},{"key":"1516_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022","author":"P-R Burgel","year":"2023","unstructured":"Burgel P-R, Sermet-Gaudelus I, Durieu I, Kanaan R, Macey J, Grenet D, et al. The French Compassionate Program of elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.02437-2022.","journal-title":"Eur Respir J"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","volume":"12","author":"P-R Burgel","year":"2024","unstructured":"Burgel P-R, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, et al. The expanded French compassionate programme for elexacaftor\u2013tezacaftor\u2013ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. Lancet Resp Med. 2024;12:888\u2013900. https:\/\/doi.org\/10.1016\/S2213-2600(24)00208-X.","journal-title":"Lancet Resp Med."},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"2301959","DOI":"10.1183\/13993003.01959-2023","volume":"63","author":"P-R Burgel","year":"2024","unstructured":"Burgel P-R, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, et al. Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint. Eur Respir J. 2024;63:2301959. https:\/\/doi.org\/10.1183\/13993003.01959-2023.","journal-title":"Eur Respir J"},{"key":"1516_CR13","unstructured":"European Medicines Agency. Kaftrio ANNEX 1-summary of product characteristics. 2020 p. 1\u201347. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf. Accessed 20 Nov 2024."},{"key":"1516_CR14","unstructured":"U.S. Food and Drug Administration. Multi-discipline review Trikafta. 2019. Report No.: 212273Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidiscplineR.pdf. Accessed 20 Nov 2024."},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","volume":"204","author":"P-R Burgel","year":"2021","unstructured":"Burgel P-R, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, et al. Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am J Respir Crit Care Med. 2021;204:64\u201373. https:\/\/doi.org\/10.1164\/rccm.202011-4153OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"PJ Barry","year":"2021","unstructured":"Barry PJ, Mall MA, \u00c1lvarez A, Colombo C, De Winter-de Groot KM, Fajac I, et al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385:815\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2100665.","journal-title":"N Engl J Med"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apm.13453","volume":"132","author":"T Bryrup","year":"2024","unstructured":"Bryrup T, Faurholt-Jepsen D, Pressler T, Henriksen EH, Leo-Hansen C, Nielsen BU, et al. Real-world data confirm elexacftor\/tezacaftor\/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis. APMIS. 2024;132:728\u201333. https:\/\/doi.org\/10.1111\/apm.13453.","journal-title":"APMIS"},{"key":"1516_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.04.013","author":"G Alicandro","year":"2024","unstructured":"Alicandro G, Gramegna A, Bellino F, Sciarrabba SC, Lanfranchi C, Contarini M, et al. Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis. J Cyst Fibros. 2024. https:\/\/doi.org\/10.1016\/j.jcf.2024.04.013.","journal-title":"J Cyst Fibros"},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/jpm11060458","volume":"11","author":"R Van Der Meer","year":"2021","unstructured":"Van Der Meer R, Wilms EB, Heijerman HGM. CFTR modulators: does one dose fit all? J Pers Med. 2021;11:458. https:\/\/doi.org\/10.3390\/jpm11060458.","journal-title":"J Pers Med."},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/jpm14101065","volume":"14","author":"S Naehrig","year":"2024","unstructured":"Naehrig S, Shad C, Breuling M, Goetschke M, Habler K, Sieber S, et al. Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis. J Pers Med. 2024;14:1065. https:\/\/doi.org\/10.3390\/jpm14101065.","journal-title":"J Pers Med."},{"key":"1516_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2024.102301","volume":"86","author":"NR Rose","year":"2024","unstructured":"Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, et al. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024;86: 102301. https:\/\/doi.org\/10.1016\/j.pupt.2024.102301.","journal-title":"Pulm Pharmacol Ther"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","volume":"23","author":"SEM Vonk","year":"2024","unstructured":"Vonk SEM, Altenburg J, Math\u00f4t RAA, Kemper EM. Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor. J Cyst Fibros. 2024;23:1007\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2024.03.010.","journal-title":"J Cyst Fibros"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","volume":"14","author":"E Choong","year":"2022","unstructured":"Choong E, Sauty A, Koutsokera A, Blanchon S, Andr\u00e9 P, Decosterd L. Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now? Pharmaceutics. 2022;14:1674. https:\/\/doi.org\/10.3390\/pharmaceutics14081674.","journal-title":"Pharmaceutics"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.14","volume":"2","author":"D Mould","year":"2013","unstructured":"Mould D, Upton R. Basic concepts in population modeling, simulation, and model-based drug development\u2014part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacom Syst Pharma. 2013;2:1\u201314. https:\/\/doi.org\/10.1038\/psp.2013.14.","journal-title":"CPT Pharmacom Syst Pharma."},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2213-2600(24)00249-2","volume":"12","author":"P-R Burgel","year":"2024","unstructured":"Burgel P-R. Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants. Lancet Respir Med. 2024;12:934\u20135. https:\/\/doi.org\/10.1016\/S2213-2600(24)00249-2.","journal-title":"Lancet Respir Med"},{"key":"1516_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116322","volume":"248","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Rouillon S, Khemakhem M, Balakirouchenane D, Lui G, Abdalla S, et al. A rapid LC\u2013MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma. J Pharm Biomed Anal. 2024;248: 116322. https:\/\/doi.org\/10.1016\/j.jpba.2024.116322.","journal-title":"J Pharm Biomed Anal"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203:1522\u201332. https:\/\/doi.org\/10.1164\/rccm.202102-0509OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","volume":"6","author":"A Tsai","year":"2020","unstructured":"Tsai A, Wu S-P, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor. Pulm Ther. 2020;6:275\u201386. https:\/\/doi.org\/10.1007\/s41030-020-00124-7.","journal-title":"Pulm Ther."},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094708. (cited 2025 Mar 17).","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1516_CR30","unstructured":"U.S. Food and Drug Administration. Clinical pharmacology and biopharmaceutics review(s) Symdeko. Report No.: 210491ORIG1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210491Orig1s000ClinPharmR.pdf. Accessed 20 Nov 2024."},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/ppul.26982","volume":"59","author":"KL Stewart","year":"2024","unstructured":"Stewart KL, Szczesniak R, Liou TG. Predicting weight gain in patients with cystic fibrosis on triple combination modulator. Pediatr Pulmonol. 2024;59:1724\u201330. https:\/\/doi.org\/10.1002\/ppul.26982.","journal-title":"Pediatr Pulmonol"},{"key":"1516_CR32","unstructured":"Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2023. 2024. p. 10\u20134. https:\/\/www.cff.org\/medical-professionals\/patient-registry. Accessed 28 Nov 2024."},{"key":"1516_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.10.009","author":"JS Ostrenga","year":"2024","unstructured":"Ostrenga JS, Robinson K, Brown AW, Goss CH, Cromwell EA. Aging with CF: characteristics of people with CF aged 40 and older in the United States. J Cyst Fibros. 2024. https:\/\/doi.org\/10.1016\/j.jcf.2024.10.009.","journal-title":"J Cyst Fibros"},{"key":"1516_CR34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0071-2024","volume":"33","author":"A Felipe Montiel","year":"2024","unstructured":"Felipe Montiel A, Fern\u00e1ndez A\u00c1, Amigo MC, Traversi L, Clofent Alarc\u00f3n D, Reyes KL, et al. The ageing of people living with cystic fibrosis: what to expect now? Eur Respir Rev. 2024;33: 240071. https:\/\/doi.org\/10.1183\/16000617.0071-2024.","journal-title":"Eur Respir Rev"},{"key":"1516_CR35","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/nu13092907","volume":"13","author":"R Bass","year":"2021","unstructured":"Bass R, Brownell JN, Stallings VA. The impact of highly effective CFTR modulators on growth and nutrition status. Nutrients. 2021;13:2907. https:\/\/doi.org\/10.3390\/nu13092907.","journal-title":"Nutrients"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.dld.2022.11.006","volume":"55","author":"R Larriba","year":"2023","unstructured":"Larriba R, Roca M, Masip E, Ca\u00f1ada-Mart\u00ednez A, Ribes-Koninckx C, Calvo-Lerma J. How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis. Dig Liver Dis. 2023;55:513\u20138. https:\/\/doi.org\/10.1016\/j.dld.2022.11.006.","journal-title":"Dig Liver Dis"},{"key":"1516_CR37","doi-asserted-by":"publisher","DOI":"10.1159\/000541326","author":"P Chu","year":"2024","unstructured":"Chu P, Mioc J, O\u2019Donovan P, Henry O. Clinical efficacy and safety of treatments for exocrine pancreatic insufficiency: a systematic literature review. Digestion. 2024. https:\/\/doi.org\/10.1159\/000541326.","journal-title":"Digestion"},{"key":"1516_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clinthera.2023.11.003","volume":"46","author":"SEM Vonk","year":"2024","unstructured":"Vonk SEM, Lub R, Weersink EJM, Beuers U, Math\u00f4t RAA, Kemper EM, et al. Stepwise introduction of elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and liver cirrhosis child-pugh A or B using clinical and therapeutic drug monitoring: a case series. Clin Ther. 2024;46:154\u20138. https:\/\/doi.org\/10.1016\/j.clinthera.2023.11.003.","journal-title":"Clin Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01516-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01516-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01516-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:42:35Z","timestamp":1749634955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01516-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01516-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"23 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Association Vaincre la Mucoviscidose, Fili\u00e8re Maladies Rares MUCO-CFTR, Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no conflict of interest directly relating to this manuscript. PRB has received personal fees for lectures\/advisory boards from Astra Zeneca, Chiesi, Insmed, Pfizer, Sanofi, MSD, Viatris, Vertex and support for travelling to meetings by Astra-Zeneca and Chiesi. CM has received personal fees for lectures\/advisory boards from Astra Zeneca, GSK, Vertex and Zambon. NC has received personal fee for an advisory board from MSD France. All other authors have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was not registered as it is not mandatory in France for real-word studies. It was approved by the Institutional Review Board of the French Society for Respiratory Medicine (\n                      Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise\n                      ) (#2020-003).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registry"}},{"value":"The study was approved by the Institutional Review Board of the French Society for Respiratory Medicine (Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise) (#2020-003). In accordance with French laws, written consent was not required, as the study did not require any intervention outside usual care. The observational nature of the study was confirmed by the Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9. Patients received written information on the study\u2019s goals and design and on the use of their medical data before inclusion. Vertex Pharmaceuticals played no role in the acquisition or analysis of data, in the writing of the manuscript, or in the decision to submit this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not publicly available but are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code used for data processing and analysis is provided in the Supplementary Information.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Concept and design: PRB, SB, JMT. Acquisition of data: LFB, GL, NC, JDS, JF, RK, IH, CM, PRB, SB. Analysis and interpretation of data: PM, PRB, SB. Drafting of the manuscript: PM, NB, FF, SB, PRB. Critical revision of the manuscript for important intellectual content: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}